Cresco Labs Q1 revenue falls less than expected

Cresco Labs

08/05/2026 11:38

Overview

U.S. cannabis producer's Q1 revenue rose, beating analyst expectations

Company posted Q1 net loss of $17 mln and adjusted EBITDA of $33 mln

Expanded dispensary footprint in Ohio and Pennsylvania, awarded Texas medical license

Outlook

Company expects benefits from medical cannabis reclassification to Schedule III in U.S.

Cresco Labs sees expanded footprint with 11 new dispensaries in Pennsylvania and Ohio

Company anticipates long-term optionality from conditional medical license award in Texas

Result Drivers

MARKET EXPANSION - Co said Q1 results reflect progress on growth initiatives, including opening new dispensaries in Ohio and Pennsylvania and starting revenue generation in Kentucky

TEXAS LICENSE - Award of conditional medical license in Texas adds long-term optionality, per management

Company press release: ID:nBw7k57Xra

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$151 mln
$148.58 mln (7 Analysts)
Q1 Net Income
-$17 mln
Q1 Adjusted EBITDA
$33 mln
Q1 Adjusted Gross Margin
50.70%
Q1 Gross Profit
$75 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Cresco Labs Inc is C$2.25, about 50% above its May 7 closing price of C$1.50

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)